These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 15167294)
41. Elevated rates of HIV infection among young Aboriginal injection drug users in a Canadian setting. Miller CL; Strathdee SA; Spittal PM; Kerr T; Li K; Schechter MT; Wood E Harm Reduct J; 2006 Mar; 3():9. PubMed ID: 16524484 [TBL] [Abstract][Full Text] [Related]
42. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797 [TBL] [Abstract][Full Text] [Related]
43. Burden of HIV infection among aboriginal injection drug users in Vancouver, British Columbia. Wood E; Montaner JS; Li K; Zhang R; Barney L; Strathdee SA; Tyndall MW; Kerr T Am J Public Health; 2008 Mar; 98(3):515-9. PubMed ID: 18235063 [TBL] [Abstract][Full Text] [Related]
44. HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway. Miller M; Mella I; Moi H; Eskild A J Acquir Immune Defic Syndr; 2003 Jul; 33(3):373-9. PubMed ID: 12843749 [TBL] [Abstract][Full Text] [Related]
45. Alarming epidemics of human immunodeficiency virus and hepatitis C virus among injection drug users in the northwestern bordering state of Punjab, India: prevalence and correlates. Panda S; Roy T; Pahari S; Mehraa J; Sharma N; Singh G; Singh J; Joseph F; Singh S; Sharma NM Int J STD AIDS; 2014 Jul; 25(8):596-606. PubMed ID: 24352120 [TBL] [Abstract][Full Text] [Related]
46. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Shapatava E; Nelson KE; Tsertsvadze T; del Rio C Drug Alcohol Depend; 2006 Apr; 82 Suppl 1():S35-8. PubMed ID: 16769443 [TBL] [Abstract][Full Text] [Related]
47. Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: an observational cohort of injecting drug users in Kabul, Afghanistan. Todd CS; Nasir A; Stanekzai MR; Fiekert K; Sipsma HL; Vlahov D; Strathdee SA Harm Reduct J; 2015 Oct; 12():22. PubMed ID: 26472126 [TBL] [Abstract][Full Text] [Related]
48. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone. Braitstein P; Li K; Kerr T; Montaner JS; Hogg RS; Wood E AIDS Care; 2006 Oct; 18(7):690-3. PubMed ID: 16971276 [TBL] [Abstract][Full Text] [Related]
49. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes. Vallejo F; Barrio G; Brugal MT; Pulido J; Toro C; Sordo L; Espelt A; Bravo MJ; J Epidemiol Community Health; 2015 Jun; 69(6):599-603. PubMed ID: 25870164 [TBL] [Abstract][Full Text] [Related]
50. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. Stark K; Müller R; Bienzle U; Guggenmoos-Holzmann I AIDS; 1996 Mar; 10(3):311-7. PubMed ID: 8882671 [TBL] [Abstract][Full Text] [Related]
51. The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users. Wood E; Kerr T; Spittal PM; Li K; Small W; Tyndall MW; Hogg RS; O'Shaughnessy MV; Schechter MT J Acquir Immune Defic Syndr; 2003 Jan; 32(1):2-8. PubMed ID: 12514408 [TBL] [Abstract][Full Text] [Related]
52. Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history. Cescon A; Chan K; Raboud JM; Burchell AN; Forrest JI; Klein MB; Loutfy MR; Machouf N; Montaner JS; Tsoukas C; Hogg RS; Cooper C; AIDS; 2014 Jan; 28(1):121-7. PubMed ID: 24413263 [TBL] [Abstract][Full Text] [Related]
53. High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province, China. Zhang L; Zhang D; Chen W; Zou X; Ling L PLoS One; 2013; 8(10):e76931. PubMed ID: 24116185 [TBL] [Abstract][Full Text] [Related]
54. Seroprevalence and correlates of HIV and HCV among injecting drug users in Edmonton, Alberta. Plitt SS; Gratrix J; Hewitt S; Conroy P; Parnell T; Lucki B; Pilling V; Anderson B; Choudri Y; Archibald CP; Singh AE Can J Public Health; 2010; 101(1):50-5. PubMed ID: 20364539 [TBL] [Abstract][Full Text] [Related]
55. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China. Tan Y; Wei QH; Chen LJ; Chan PC; Lai WS; He ML; Kung HF; Lee SS PLoS One; 2008; 3(10):e3608. PubMed ID: 18974888 [TBL] [Abstract][Full Text] [Related]
56. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California. Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432 [TBL] [Abstract][Full Text] [Related]
57. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. Lumbreras B; Jarrín I; del Amo J; Pérez-Hoyos S; Muga R; García-de la Hera M; Ferreros I; Sanvisens A; Hurtado I; Hernández-Aguado I AIDS; 2006 Jan; 20(1):111-6. PubMed ID: 16327326 [TBL] [Abstract][Full Text] [Related]
58. Risk of Complications After THA Increases Among Patients Who Are Coinfected With HIV and Hepatitis C. Mahure SA; Bosco JA; Slover JD; Vigdorchik J; Iorio R; Schwarzkopf R Clin Orthop Relat Res; 2018 Feb; 476(2):356-369. PubMed ID: 29529669 [TBL] [Abstract][Full Text] [Related]
59. Binge drug use independently predicts HIV seroconversion among injection drug users: implications for public health strategies. Miller CL; Kerr T; Frankish JC; Spittal PM; Li K; Schechter MT; Wood E Subst Use Misuse; 2006; 41(2):199-210. PubMed ID: 16393742 [TBL] [Abstract][Full Text] [Related]
60. Changes in blood-borne infection risk among injection drug users. Mehta SH; Astemborski J; Kirk GD; Strathdee SA; Nelson KE; Vlahov D; Thomas DL J Infect Dis; 2011 Mar; 203(5):587-94. PubMed ID: 21282191 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]